Biohaven Ltd. (BHVN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BHVN currently has 148M outstanding shares. with limited dilution risk as only 23M additional shares (15.6%) are authorized for issuance. The company has significantly diluted shareholders by 59.55% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 04, 2026 |
10-Q filing | 147.6M shares outstanding |
150M | 23M |
| Nov 13, 2025 |
8-K filing: Biohaven Ltd. completed a public offering of 26,833,334 common shares, including the exercise of the underwriters' option, at $7.50 per share, resulting in gross proceeds of approximately $200 million. ($200.0M proceeds) |
110M | 23M |
| Nov 10, 2025 |
10-Q filing | 105.8M shares outstanding |
110M | 23M |
| Aug 15, 2025 |
8-K filing: Biohaven Ltd. filed a prospectus supplement regarding the resale of 3,588,688 common shares by a selling shareholder, issued as consideration for an amendment to a purchase agreement. |
100M | 23M |
| Aug 11, 2025 |
10-Q filing | 102.4M shares outstanding |
100M | 23M |
| May 12, 2025 |
10-Q filing | 101.9M shares outstanding |
100M | 23M |
| Mar 03, 2025 |
10-K filing | 102.1M shares outstanding |
100M | 23M |
| Nov 12, 2024 |
10-Q filing | 94.4M shares outstanding |
94M | 23M |
| Oct 02, 2024 |
8-K filing: Biohaven Ltd. completed a public offering of 6,052,631 common shares at $47.50 per share, resulting in gross proceeds of approximately $287.5 million. ($287.5M proceeds) |
95M | 23M |
| Aug 16, 2024 |
8-K filing: Biohaven Ltd. filed a prospectus supplement to its Registration Statement on Form S-3 with respect to the resale by a selling shareholder of 1,872,874 common shares that were issued by the Company to such selling shareholder as share consideration. |
88M | 23M |
| Aug 09, 2024 |
10-Q filing | 87.8M shares outstanding |
88M | 23M |
| May 17, 2024 |
8-K filing: Biohaven Ltd. filed a prospectus supplement related to the resale of 211,418 common shares by selling shareholders, which were initially issued as share consideration in connection with certain transactions and business arrangements. |
82M | 23M |
| May 09, 2024 |
10-Q filing | 81.6M shares outstanding |
82M | 23M |
| Apr 22, 2024 |
8-K filing: Biohaven Ltd. completed a public offering of 6,451,220 common shares at $41.00 per share, resulting in gross proceeds of approximately $264.5 million before deductions. ($264.5M proceeds) |
82M | 23M |
| Mar 12, 2024 |
8-K filing: Biohaven Ltd. filed a prospectus supplement regarding the resale of 45,883 common shares by selling shareholders. |
82M | 23M |
| Feb 29, 2024 |
10-K filing | 81.6M shares outstanding |
82M | 23M |
| Nov 14, 2023 |
10-Q filing | 80.2M shares outstanding |
80M | 23M |
| Oct 05, 2023 |
8-K filing: Biohaven Ltd. completed a public offering of 11,761,363 common shares at $22.00 per share on October 5, 2023, including the full exercise of the underwriters' option, resulting in gross proceeds of approximately $258.7 million. ($258.7M proceeds) |
68M | 23M |
| Jul 31, 2023 |
10-Q filing | 68.2M shares outstanding |
68M | 23M |
| May 12, 2023 |
10-Q filing | 68.2M shares outstanding |
68M | 23M |
| Mar 23, 2023 |
10-K filing | 68.2M shares outstanding |
68M | 23M |
| Nov 09, 2022 |
10-Q filing | 68.2M shares outstanding |
68M | 23M |
| Oct 20, 2022 |
S-1/A filing: Biohaven Ltd. is offering 20,000,000 common shares with an option for underwriters to purchase an additional 3,000,000 common shares, intending to use the net proceeds for general corporate purposes. |
39M | 23M |
| Oct 18, 2022 |
S-1 filing: Biohaven Ltd. is offering 20,000,000 common shares (or 3,000,000 common shares if the underwriters exercise in full their option to purchase additional common shares) at a price of $10.35 per share. The company intends to use the net proceeds from this offering for general corporate purposes. |
39M | 40M |